TP53 and colorectal carcinoma: Among the 469 CRC patients with targeted exome-sequencing data, 198 patients (42.2%) showed nonsynonymous SNVs, 25 patients (5.3%) showed indels, 60 patients (12.8%) showed stop–gain mutations and 186 patients (39.7%) had wild-type TP53 (Fig. 2b).